About the Editors

Editor-in-Chief

Jan Paul Medema, Laboratory of Experimental Oncology and Radiobiology (LEXOR), University of Amsterdam, Netherlands

Jan Paul Medema studied Chemistry in Leiden, the Netherlands, graduating in 1991 with a specialisation in biochemistry and medical biochemistry. He continued his training under the guidance of Professor Hans Bos at the Univeristy of Utrecht and received his PhD in 1996 on the topic of the oncoprotein p21Ras. He then went on to study the role of programmed cell death in tumor biology and immunology in order to understand the basic concepts of cell death signalling and the way these are perturbed in cancer. He unravelled several modes of cell death escape, specifically in the face of a cytotoxic immune response. Later, his work moved into the direction of cancer heterogeneity and its role in cell death resistance, tumor growth and therapy response, centering around the role of cancer stem cells in these processes, as well as the role of inter-patient heterogeneity in the aggressiveness of tumors. Currently, Professor Medema is the Head of the Laboratory of Experimental Oncology and Radiobiology (LEXOR) in the Academic Medical Center of the University of Amsterdam, which has developed several research lines focusing on the mechanisms of survival/cell death resistance of tumor cells against therapeutic interventions.

Associate Editors

Maarten Bijlsma, University of Amsterdam, Amsterdam, The Netherlands

Maarten Bijlsma received his master’s degree in molecular biology from the University of Amsterdam in 2002. His PhD studies at the Medicine Faculty of that same university centered on the contributions and mechanisms of Hedgehog signaling in development, cardiovascular disease, and cancer. He received his doctorate in 2008 and then, supported by KWF Dutch Cancer Society fellowship, did his postdoctoral research in the lab of Henk Roelink at UC Berkeley. Here, he further investigated Hedgehog signaling in development and cancer, discovering several previously unrecognized paradigms and mechanisms in this signaling pathway.  Since 2010, he is a group leader at the Amsterdam UMC, location AMC, where his group works on pancreatic and esophageal cancer, cancers that depend on tumor-stroma interaction and are suspected to at least in part be driven by aberrant Hedgehog signaling. The research in his group ranges from cell biology, translational work including biomarker development, delineation of intra- and inter-tumor heterogeneity, to the design of clinical studies with collaborators from clinical departments. 

Jerry Edward Chipuk, Mount Sinai School of Medicine, New York, NY, USA

Jerry Edward Chipuk is an Assistant Professor in the Department of Oncological Sciences at the Icahn School of Medicine at Mount Sinai in New York City. He earned a Ph.D. in Pharmacology and Cancer Biology at Case Western Reserve University, and then was a post-doctoral fellow in the laboratory of Douglas R. Green, Ph.D. at the La Jolla Institute for Allergy and Immunology and St Jude Children's Research Hospital. Dr Chipuk joined the faculty at Mount Sinai and became co-appointed in the Department of Dermatology, Tisch Cancer Institute, and the Diabetes, Obesity, and Metabolism Institute. His laboratory is focused on how mitochondrial shape and function contribute to disease etiology, prognosis, and treatment.

Vincenzo De Laurenzi, Università 'G. d'Annunzio' Chieti-Pescara, Chieti, Italy

Vincenzo De Laurenzi received his MD in 1990 from the University of Rome Tor Vergata and a PhD in Enzimology from the same University in 1994.
Besides working for many years in the laboratory of Gerry Melino in Rome he has worked at the NIH, Bethesda Maryland investigating the molecular mechanisms of skin deseases and more recently at the MRC toxicology unit in Leicester UK. Currently he is Associate Professor of Clinical Biochemistry and Molecular Biology at the University "G. D’Annunzio" in Chieti. His main scientific interests are: the study of the regulation and function of the p53 family of transcription factors, mainly in cancer development and the role of Histone Locus Bodies components in the regulation of cell cycle.

Philip Gregory, University of South Australia, Adelaide, Australia
Philip Gregory is Associate Professor and leader of the ‘Gene Regulation in Cancer’ laboratory at the University of South Australia in Adelaide, Australia since 2015. He has made pioneering discoveries in the areas of microRNA function, circular RNA biogenesis and mechanisms regulating alternative splicing during cancer progression. His key interests lie in the regulation of gene expression during epithelial-mesenchymal transition, a key process governing cancer metastasis and response to therapies.

Lev Kats, Peter MacCallum Cancer Centre, Melbourne, Australia

Dr Lev Kats is a group leader within the Translational Haematology Program at the Peter MacCallum Cancer Centre. He was awarded his PhD in 2009 from Monash University and completed his post-doctoral training at Beth Israel Deaconess Centre/Harvard Medical School. Dr Kats is interested in epigenetic regulation of haematopoiesis and leukaemia and his laboratory uses mouse models to understand how specific genes contribute to leukaemia initiation and maintenance.

Jean-Ehrland Ricci, INSERM, Nice, France

Jean-Ehrland Ricci is leading the ‘Metabolic control of cell death' team at the Mediterranean Center for Medical Research (C3M), INSERM U1065 in Nice, France. He started his career studying the death receptor- and T cell receptor-induced apoptosis and obtained his Ph.D. from the University of Nice Sophia-Antipolis in 2000. He then moved to San Diego, CA in the ‘La Jolla Institute for Allergy and Immunology’ institute to work under the supervision of Dr Douglas R Green. He studied the link between metabolism (mitochondrial and glycolytic) and the regulation of caspase dependent and independent cell death. Jean-Ehrland started his lab in Nice in 2006, where his team studies the role of metabolism in cancers, cell death and immune regulation.